PCDC Teams

The PCDC teams (also known as Units) are focused on developing and testing new molecular and imaging biomarkers to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions and identify individuals who are at high risk of developing PDAC and are candidates for early intervention. The eight PCDC teams are listed below. Principal Investigators are listed in alphabetical order by last name.

Principal Investigator(s) Institution(s) Project Title
Ajay Goel, PhD
Daniel D. Von Hoff, MD, FACP
Beckman Research Institute, City of Hope Comprehensive Cancer Center; Translational Genomics Research Institute Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
Michael G. Goggins, PhD Johns Hopkins University Using Markers to Improve Pancreatic Cancer Screening and Surveillance
Michael (Tony) A. Hollingsworth, PhD University of Nebraska Medical Center Pancreatic Cancer Detection Consortium – Biomarker Discovery and Validation
Gloria M. Petersen, PhD
Kenneth Zaret, PhD
Mayo Clinic; University of Pennsylvania Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer
Subrata Sen, PhD
Ann Killary, PhD
The University of Texas MD Anderson Cancer Center Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer
Julie L. Sutcliffe, PhD University of California, Davis Peptide-based targeted molecular imaging for early detection in pancreatic cancer
Andrei Iagaru, MD
Walter G. Park, MD, MS
Stanford University Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma
Brian M. Wolpin, MD, MPH Dana Farber Cancer Institute; Harvard Medical School Circulating Biomarker Consortium for Pancreatic Cancer Early Detection